Secretory TAT-peptide-mediated Protein Transduction of LIF Receptor α-chain Distal Cytoplasmic Motifs into Human Myeloid HL-60 Cells

Overview

Journal Braz J Med Biol Res

Specialties Biology
General Medicine

Date 2012 Jun 21

PMID 22714809

Authors

Q Sun

J Xiong

J Lu

S Xu

Y Li

X P Zhong

G K Gao

H Q Liu

Affiliations

Soon will be listed here.

Abstract

The distal cytoplasmic motifs of leukemia inhibitory factor receptor α-chain (LIFRα-CT3) can independently induce intracellular myeloid differentiation in acute myeloid leukemia (AML) cells by gene transfection; however, there are significant limitations in the potential clinical use of these motifs due to liposome-derived genetic modifications. To produce a potentially therapeutic LIFRα-CT3 with cell-permeable activity, we constructed a eukaryotic expression pcDNA3.0-TAT-CT3-cMyc plasmid with a signal peptide (ss) inserted into the N-terminal that codes for an ss-TAT-CT3-cMyc fusion protein. The stable transfection of Chinese hamster ovary (CHO) cells via this vector and subsequent selection by Geneticin resulted in cell lines that express and secrete TAT-CT3-cMyc. The spent medium of pcDNA3.0-TAT-CT3-cMyc-transfected CHO cells could be purified using a cMyc-epitope-tag agarose affinity chromatography column and could be detected via SDS-PAGE, with antibodies against cMyc-tag. The direct administration of TAT-CT3-cMyc to HL-60 cell culture media caused the enrichment of CT3-cMyc in the cytoplasm and nucleus within 30 min and led to a significant reduction of viable cells (P < 0.05) 8 h after exposure. The advantages of using this mammalian expression system include the ease of generating TAT fusion proteins that are adequately transcripted and the potential for a sustained production of such proteins in vitro for future AML therapy.

References

Dietz G, Bahr M . Delivery of bioactive molecules into the cell: the Trojan horse approach. Mol Cell Neurosci. 2004; 27(2):85-131. DOI: 10.1016/j.mcn.2004.03.005. View

Zhao J, Gao P, Xiao W, Fan L, Wang F, Li S . A novel human derived cell-penetrating peptide in drug delivery. Mol Biol Rep. 2010; 38(4):2649-56. DOI: 10.1007/s11033-010-0406-6. View

Abes R, Arzumanov A, Moulton H, Abes S, Ivanova G, Gait M . Arginine-rich cell penetrating peptides: design, structure-activity, and applications to alter pre-mRNA splicing by steric-block oligonucleotides. J Pept Sci. 2008; 14(4):455-60. DOI: 10.1002/psc.979. View

McAdams H, Arkin A . Stochastic mechanisms in gene expression. Proc Natl Acad Sci U S A. 1997; 94(3):814-9. PMC: 19596. DOI: 10.1073/pnas.94.3.814. View

Li B, Wang H, Dai J, Ji J, Qian W, Zhang D . Construction and characterization of a humanized anti-human CD3 monoclonal antibody 12F6 with effective immunoregulation functions. Immunology. 2005; 116(4):487-98. PMC: 1802437. DOI: 10.1111/j.1365-2567.2005.02247.x. View

Bach J, Borta H, Ackermann W, Faust F, Borchers O, Schrader M . The secretory granule protein syncollin localizes to HL-60 cells and neutrophils. J Histochem Cytochem. 2006; 54(8):877-88. DOI: 10.1369/jhc.5A6792.2006. View

Sun Q, Wang J, Xiong J, Yang L, Liu H . Free LIF receptor α-chain distal cytoplasmic motifs enhance Jak2-independent STAT3 phosphorylation and induce differentiation in HL-60 cells. Oncol Rep. 2011; 26(2):399-404. DOI: 10.3892/or.2011.1289. View

Barka T, Gresik E, Henderson S . Production of cell lines secreting TAT fusion proteins. J Histochem Cytochem. 2004; 52(4):469-77. DOI: 10.1177/002215540405200405. View

Dostal L, Chen C, Wang A, Welfle H . Partial B-to-A DNA transition upon minor groove binding of protein Sac7d monitored by Raman spectroscopy. Biochemistry. 2004; 43(30):9600-9. DOI: 10.1021/bi049192r. View

10.

Guo S, Shen X, Yang J, Yuan J, Yang R, Mao K . TIMP-1 mediates the inhibitory effect of interleukin-6 on the proliferation of a hepatocarcinoma cell line in a STAT3-dependent manner. Braz J Med Biol Res. 2007; 40(5):621-31. DOI: 10.1590/s0100-879x2007000500004. View

11.

Fang Z, Dong C, Chen Z, Zhou B, Liu N, Lan H . Transcriptional regulation of survivin by c-Myc in BCR/ABL-transformed cells: implications in anti-leukaemic strategy. J Cell Mol Med. 2009; 13(8B):2039-2052. PMC: 6512385. DOI: 10.1111/j.1582-4934.2008.00549.x. View

12.

Denicourt C, Dowdy S . Protein transduction technology offers novel therapeutic approach for brain ischemia. Trends Pharmacol Sci. 2003; 24(5):216-8. DOI: 10.1016/S0165-6147(03)00074-9. View

13.

Liu H, Dan J, Tang S, Wu S . Involving of the cytoplasmic region of leukemia inhibitory factor receptor alpha subunit, IL-6 related signal transducer-gp130 or fas death domain for MAPK p42/44 activation in HL-60 cell with LIF or anti-Fas IgG. Mol Cell Biochem. 2001; 217(1-2):113-20. DOI: 10.1023/a:1007220627845. View

14.

Gaken J, Jiang J, Daniel K, Van Berkel E, Hughes C, Kuiper M . Fusagene vectors: a novel strategy for the expression of multiple genes from a single cistron. Gene Ther. 2001; 7(23):1979-85. DOI: 10.1038/sj.gt.3301341. View

15.

Tikhonov I, Ruckwardt T, Berg S, Hatfield G, Pauza C . Furin cleavage of the HIV-1 Tat protein. FEBS Lett. 2004; 565(1-3):89-92. DOI: 10.1016/j.febslet.2004.03.079. View

16.

Ting L, Bo W, Li R, Chen X, Wang Y, Jun Z . AMP-activated protein kinase supports the NGF-induced viability of human HeLa cells to glucose starvation. Mol Biol Rep. 2009; 37(6):2593-8. DOI: 10.1007/s11033-009-9780-3. View

17.

Flinterman M, Farzaneh F, Habib N, Malik F, Gaken J, Tavassoli M . Delivery of therapeutic proteins as secretable TAT fusion products. Mol Ther. 2008; 17(2):334-42. PMC: 2835060. DOI: 10.1038/mt.2008.256. View

18.

Muthumani K, Lambert V, Shanmugam M, Thieu K, Choo A, Chung J . Anti-tumor activity mediated by protein and peptide transduction of HIV viral protein R (Vpr). Cancer Biol Ther. 2008; 8(2):180-7. DOI: 10.4161/cbt.8.2.7205. View

19.

Pan C, Lu B, Chen H, Bishop C . Reprogramming human fibroblasts using HIV-1 TAT recombinant proteins OCT4, SOX2, KLF4 and c-MYC. Mol Biol Rep. 2009; 37(4):2117-24. PMC: 3772671. DOI: 10.1007/s11033-009-9680-6. View

20.

Lang Q, Zhang H, Li J, Xie F, Zhang Y, Wan B . 3-Hydroxyflavone inhibits endogenous Aurora B and induces growth inhibition of cancer cell line. Mol Biol Rep. 2009; 37(3):1577-83. DOI: 10.1007/s11033-009-9562-y. View